What Happened?
Cambridge, MA-based Genocea Resigned Raymond Stapleton as Executive Vice President and Chief Technology Officer
About the Company
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
About the Person
Raymond Stapleton is Chief Technology Officer at Vaxart. Previously, Raymond held various senior IT leadership roles in the industry.
Info Source
News
Short Profile